SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Becton, Dickinson and Company BDXB NYSE

NYSE • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Becton, Dickinson and Company (BDXB) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $48.16. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $21.8B, +5%/yr average growth. Net income is $1.7B, growing at -1.1%/yr. Net profit margin is 7.7% (thin). Gross margin is 45.4% (+0.5 pp trend).

Balance sheet: total debt is $19.2B against $25.4B equity (Debt-to-Equity (D/E) ratio 0.76, moderate). Current ratio is 1.11 (adequate). Debt-to-assets is 34.7%. Total assets: $55.3B.

Analyst outlook: 16 / 30 analysts rate BDXB as buy (53%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 100/100 (Pass), Health 50/100 (Partial), Moat 73/100 (Pass), Future 40/100 (Partial), Income 45/100 (Partial).

BDXB SharesGrow Score Overview

64/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 40/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 73/100

Gross margin is + market cap

FUTURE 40/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BDXB

BDXB trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

BDXB: +5%/yr revenue is, -1.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

BDXB: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet BDXB: Debt-to-Equity (D/E) ratio 0.76 (moderate), Current ratio is 1.11 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BDXB: Gross margin is 45.4% (+0.5 pp trend), $14B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 73/100. ≥ 70 = Pass.

View details →

Analyst outlook: 16 / 30 analysts rate BDXB as buy (53%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

BDXB: Net profit margin is 7.7%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range45.85-52.52

Volume2.76M

Avg Volume (30D)449.58K

Market Cap$13.69B

Beta (1Y)0.56

Dividend Yield$3.0000

Share Statistics

EPS (TTM)5.84

Shares Outstanding$286.61M

IPO Date2020-05-21

Employees77,000

CEOThomas E. Polen Jr.

Financial Highlights & Ratios

Revenue (TTM)$21.84B

Gross Profit$9.92B

EBITDA$4.96B

Net Income$1.68B

Operating Income$2.58B

Total Cash$859M

Total Debt$19.18B

Net Debt$18.33B

Total Assets$55.33B

Price / Earnings (P/E)8.2

Price / Sales (P/S)0.63

Analyst Forecast

Rating ConsensusBuy

Analysts Covering30

Buy 53% Hold 43% Sell 3%

Company Info

CountryUS

ExchangeNYSE

CurrencyUSD

ISINUS0758874061

Price Chart

BDXB

Becton, Dickinson and Company ↗ · NYSE

Healthcare • Medical - Instruments & Supplies

45.85 52WK RANGE 52.52

People Also View

Boston Scientific Corporation

Brighthouse Financial, Inc.

Brighthouse Financial, Inc.

Brighthouse Financial, Inc.

American Electric Power Company, Inc.

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message